NCT05772130 Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study
| NCT ID | NCT05772130 |
| Status | Recruiting |
| Phase | — |
| Sponsor | City of Hope Medical Center |
| Condition | Hematopoietic and Lymphoid System Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2023-02-14 |
| Primary Completion | 2026-12-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 240 participants in total. It began in 2023-02-14 with a primary completion date of 2026-12-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial tests whether provider-mediated communication of genetic testing results to at-risk relatives of cancer patients can help improve genetic counseling and testing rates. Approximately 15% of people with cancer have an inherited form of cancer due to changes in a gene that they have inherited from one of their parents. These changes increase a person's risk for developing cancer. Most people who have an inherited harmful change in a cancer risk gene don't know that they have it and are therefore not able to get the health care that they need. The primary reason for this problem has been a lack of genetic counseling and testing for cancer patients and patients with a strong family history of cancer. Another reason for this lack of awareness is that, when cancer runs in a family, the patient who carries the gene change usually has to communicate the genetic risk information to their family members. When this process doesn't work well, family members may not know that they need to get genetic testing and then may not get potentially life-saving care. Provider-mediated contact to discuss genetic test results may help improve rates of genetic testing among at-risk relatives of patients with a family cancer syndrome.
Eligibility Criteria
Inclusion Criteria: * PATIENTS: Enrolled in City of Hope (COH) institutional review board (IRB) 07047 or have been seen by COH Genetics for genetic testing * PATIENTS: Have an pathogenic/ likely pathogenic germline variant * PATIENTS: Fluent in English * PATIENTS: Age \>= 18 years * PATIENTS: Willing to provide contact information for eligible first-degree relatives * PATIENTS: \>= 2 first-degree relatives that are eligible for genetic testing and reside in the United States of America * FIRST-DEGREE RELATIVES: Proband is a COH patient and has consented to this study * FIRST-DEGREE RELATIVES: First-degree relative of proband * FIRST-DEGREE RELATIVES: Resides within the United States * FIRST-DEGREE RELATIVES: Has not undergone genetic testing for the known familial variant * FIRST-DEGREE RELATIVES: Are fluent in English * FIRST-DEGREE RELATIVES: Age \>= 18 years Exclusion Criteria: * PATIENTS: Unable to provide informed consent * PATIENTS: =\< 2 at-risk first-degree relatives who are eligible for genetic testing and/or reside within the United States * PATIENTS: Unwilling to provide contact information for family members * FIRST-DEGREE RELATIVES: Unable or unwilling to provide informed consent * FIRST-DEGREE RELATIVES: Have undergone genetic testing for the known familial variant * FIRST-DEGREE RELATIVES: Resides outside of the United States
Contact & Investigator
Stacy W Gray
PRINCIPAL INVESTIGATOR
City of Hope Medical Center
Frequently Asked Questions
Who can join the NCT05772130 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematopoietic and Lymphoid System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05772130 currently recruiting?
Yes, NCT05772130 is actively recruiting participants. Visit ClinicalTrials.gov or contact City of Hope Medical Center to inquire about joining.
Where is the NCT05772130 trial being conducted?
This trial is being conducted at Duarte, United States.
Who is sponsoring the NCT05772130 clinical trial?
NCT05772130 is sponsored by City of Hope Medical Center. The principal investigator is Stacy W Gray at City of Hope Medical Center. The trial plans to enroll 240 participants.